ES2361584T3 - Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos. - Google Patents
Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos. Download PDFInfo
- Publication number
- ES2361584T3 ES2361584T3 ES07838415T ES07838415T ES2361584T3 ES 2361584 T3 ES2361584 T3 ES 2361584T3 ES 07838415 T ES07838415 T ES 07838415T ES 07838415 T ES07838415 T ES 07838415T ES 2361584 T3 ES2361584 T3 ES 2361584T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- mmol
- compound
- dmso
- dioxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pregnancy & Childbirth (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84522706P | 2006-09-15 | 2006-09-15 | |
| US845227P | 2006-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2361584T3 true ES2361584T3 (es) | 2011-06-20 |
Family
ID=38983295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07838415T Active ES2361584T3 (es) | 2006-09-15 | 2007-09-14 | Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos. |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8648096B2 (https=) |
| EP (1) | EP2076260B1 (https=) |
| JP (1) | JP5567339B2 (https=) |
| KR (1) | KR20090050107A (https=) |
| CN (2) | CN101534820A (https=) |
| AR (1) | AR062875A1 (https=) |
| AT (1) | ATE502634T1 (https=) |
| CA (1) | CA2663376C (https=) |
| CL (1) | CL2007002670A1 (https=) |
| CO (1) | CO6180446A2 (https=) |
| CR (1) | CR10696A (https=) |
| CY (1) | CY1112558T1 (https=) |
| DE (1) | DE602007013436D1 (https=) |
| DK (1) | DK2076260T3 (https=) |
| ES (1) | ES2361584T3 (https=) |
| HR (1) | HRP20110261T1 (https=) |
| IL (1) | IL197566A0 (https=) |
| MX (1) | MX2009002666A (https=) |
| NI (1) | NI200900031A (https=) |
| NZ (1) | NZ575689A (https=) |
| PE (1) | PE20080832A1 (https=) |
| PL (1) | PL2076260T3 (https=) |
| PT (1) | PT2076260E (https=) |
| RS (1) | RS51725B (https=) |
| RU (1) | RU2009114159A (https=) |
| SI (1) | SI2076260T1 (https=) |
| TW (1) | TW200819435A (https=) |
| UA (1) | UA95975C2 (https=) |
| WO (1) | WO2008033567A1 (https=) |
| ZA (1) | ZA200901852B (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1797068B1 (en) * | 2004-09-03 | 2013-10-09 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
| MX2007016290A (es) | 2005-06-30 | 2008-03-10 | Celgene Corp | Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona. |
| CL2007002670A1 (es) * | 2006-09-15 | 2008-05-16 | Celgene Corp Soc Organizada Ba | Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis. |
| US20100160368A1 (en) * | 2008-08-18 | 2010-06-24 | Gregory Jefferson J | Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy |
| PT2358697E (pt) | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| SI2378876T1 (sl) | 2008-12-19 | 2019-05-31 | Medicis Pharmaceutical Corporation | Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze |
| GEP20156418B (en) | 2009-07-13 | 2016-01-11 | Medicis Pharmaceutical Corp | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| US11295846B2 (en) | 2011-12-21 | 2022-04-05 | Deka Products Limited Partnership | System, method, and apparatus for infusing fluid |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| KR102028793B1 (ko) | 2013-03-14 | 2019-10-07 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
| WO2014153214A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2970137A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| JP2016518336A (ja) | 2013-03-14 | 2016-06-23 | エピザイム，インコーポレイティド | Ｐｒｍｔ１阻害剤としてのピラゾール誘導体およびその使用 |
| WO2014153100A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9765035B2 (en) | 2013-03-14 | 2017-09-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| NZ629456A (en) | 2013-04-17 | 2017-06-30 | Signal Pharm Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| MX2017001620A (es) | 2014-08-07 | 2017-05-10 | Calithera Biosciences Inc | Formas cristalinas de inhibidores de glutaminasa. |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US10449168B2 (en) | 2015-08-31 | 2019-10-22 | The University Of Toledo | Potent phthalate inhibitors of aspartate N-acetyltransferase and selective aspartate pathway inhibitors |
| CN109071516B (zh) | 2015-12-15 | 2021-08-31 | 阿斯利康(瑞典)有限公司 | 新颖的化合物 |
| US10759808B2 (en) * | 2016-04-06 | 2020-09-01 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| KR20190084063A (ko) | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 |
| WO2018106870A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN111372585A (zh) | 2017-11-16 | 2020-07-03 | C4医药公司 | 用于靶蛋白降解的降解剂和降解决定子 |
| JP2021515013A (ja) | 2018-03-06 | 2021-06-17 | アイカーン スクール オブ メディスン アット マウント シナイ | セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法 |
| EP3773576A4 (en) | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
| FI3784663T3 (fi) * | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| EP3810145A4 (en) | 2018-06-21 | 2022-06-01 | Icahn School of Medicine at Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| AR119715A1 (es) * | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| JP7503851B2 (ja) | 2019-05-06 | 2024-06-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 |
| WO2021080931A1 (en) | 2019-10-21 | 2021-04-29 | Celgene Corporation | Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneand salts thereof, and compositions comprising the same and their use |
| CN115919870B (zh) | 2019-10-21 | 2024-07-02 | 新基公司 | 化合物在制备用于治疗慢性淋巴细胞白血病的药物中的用途 |
| IL292305A (en) * | 2019-10-21 | 2022-06-01 | Celgene Corp | Methods for the treatment of hematological cancer and the use of associated biomarkers for 2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isodonyl 1,3-discussion |
| CN110746400B (zh) * | 2019-11-07 | 2021-12-17 | 郑州大学 | 一种靶向雄激素受体的荧光探针及其制备方法 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| EP4446324A4 (en) * | 2021-12-08 | 2026-05-06 | Gluetacs Therapeutics Shanghai Co Ltd | Ligand compounds for e3 ubiquitin ligase, protein degraders developed on basis of ligand compounds, and uses thereof |
| CA3249074A1 (en) | 2022-06-06 | 2023-12-14 | C4 Therapeutics, Inc. | BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| TR200101502T2 (tr) * | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| EP1569907B1 (en) * | 2002-12-13 | 2016-03-09 | YM BioSciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
| US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| MX2007016290A (es) * | 2005-06-30 | 2008-03-10 | Celgene Corp | Procesos para la preparacion de compuestos de 4-amino-2(2,6-dioxopiperidin-3-il)isoindolin-1,3-diona. |
| CL2007002670A1 (es) * | 2006-09-15 | 2008-05-16 | Celgene Corp Soc Organizada Ba | Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis. |
-
2007
- 2007-09-14 CL CL200702670A patent/CL2007002670A1/es unknown
- 2007-09-14 NZ NZ575689A patent/NZ575689A/en not_active IP Right Cessation
- 2007-09-14 HR HR20110261T patent/HRP20110261T1/hr unknown
- 2007-09-14 AT AT07838415T patent/ATE502634T1/de active
- 2007-09-14 SI SI200730569T patent/SI2076260T1/sl unknown
- 2007-09-14 US US11/901,291 patent/US8648096B2/en active Active
- 2007-09-14 DE DE602007013436T patent/DE602007013436D1/de active Active
- 2007-09-14 PL PL07838415T patent/PL2076260T3/pl unknown
- 2007-09-14 CN CNA2007800424312A patent/CN101534820A/zh active Pending
- 2007-09-14 WO PCT/US2007/020201 patent/WO2008033567A1/en not_active Ceased
- 2007-09-14 EP EP07838415A patent/EP2076260B1/en active Active
- 2007-09-14 KR KR1020097006986A patent/KR20090050107A/ko not_active Withdrawn
- 2007-09-14 JP JP2009528337A patent/JP5567339B2/ja active Active
- 2007-09-14 ZA ZA200901852A patent/ZA200901852B/xx unknown
- 2007-09-14 DK DK07838415.3T patent/DK2076260T3/da active
- 2007-09-14 CN CN2013102182141A patent/CN103382197A/zh active Pending
- 2007-09-14 RS RS20110258A patent/RS51725B/sr unknown
- 2007-09-14 ES ES07838415T patent/ES2361584T3/es active Active
- 2007-09-14 CA CA2663376A patent/CA2663376C/en active Active
- 2007-09-14 TW TW096134612A patent/TW200819435A/zh unknown
- 2007-09-14 RU RU2009114159/15A patent/RU2009114159A/ru not_active Application Discontinuation
- 2007-09-14 UA UAA200903664A patent/UA95975C2/ru unknown
- 2007-09-14 PT PT07838415T patent/PT2076260E/pt unknown
- 2007-09-14 MX MX2009002666A patent/MX2009002666A/es active IP Right Grant
- 2007-09-17 AR ARP070104112A patent/AR062875A1/es unknown
- 2007-09-17 PE PE2007001253A patent/PE20080832A1/es not_active Application Discontinuation
-
2009
- 2009-03-12 IL IL197566A patent/IL197566A0/en unknown
- 2009-03-13 NI NI200900031A patent/NI200900031A/es unknown
- 2009-03-30 CR CR10696A patent/CR10696A/es not_active Application Discontinuation
- 2009-04-03 CO CO09034806A patent/CO6180446A2/es not_active Application Discontinuation
-
2011
- 2011-05-20 CY CY20111100500T patent/CY1112558T1/el unknown
-
2013
- 2013-12-30 US US14/144,292 patent/US20140113935A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2361584T3 (es) | Compuestos de n-metilaminometil-isoindol y composiciones que los comprenden y métodos que usan los mismos. | |
| ES2385680T3 (es) | Derivados de quinazolinona 5 sustituidos como agentes antitumorales | |
| US9834538B2 (en) | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | |
| ES2426350T3 (es) | Compuestos de isoindolina sustituidos en 5 | |
| ES2734253T3 (es) | Derivados de isoindolina 4'-O-sustituidos y composiciones que los comprenden y métodos de uso de los mismos | |
| ES2434946T3 (es) | Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo | |
| ES2736450T3 (es) | Compuestos de isoindolina 5-sustituida | |
| HK1167398B (en) | 5-substituted quinazolinone derivatives as anti-cancer agents |